{
    "paper_id": "7c5090ccc207ebe0bd0b98b85f9b746971fb3ce6",
    "metadata": {
        "title": "Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy 1 donors 2 3",
        "authors": [
            {
                "first": "Julian",
                "middle": [],
                "last": "Braun",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Lucie",
                "middle": [],
                "last": "Loyal",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Marco",
                "middle": [],
                "last": "Frentsch",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin 24",
                    "location": {
                        "postCode": "25",
                        "settlement": "Berlin"
                    }
                },
                "email": ""
            },
            {
                "first": "Daniel",
                "middle": [],
                "last": "Wendisch",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Philipp",
                "middle": [],
                "last": "Georg",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Florian",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Kurth",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Stefan",
                "middle": [],
                "last": "Hippenstiel",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Manuela",
                "middle": [],
                "last": "Dingeldey",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Beate",
                "middle": [],
                "last": "Kruse",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Florent",
                "middle": [],
                "last": "Fauchere",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Emre",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Baysal",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Maike",
                "middle": [],
                "last": "Mangold",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Larissa",
                "middle": [],
                "last": "Henze",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Roland",
                "middle": [],
                "last": "Lauster",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Marcus",
                "middle": [
                    "A"
                ],
                "last": "Mall",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": ""
            },
            {
                "first": "Kirsten",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Beyer",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jobst",
                "middle": [],
                "last": "R\u00f6hmel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J\u00fcrgen",
                "middle": [],
                "last": "Schmitz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Stefan",
                "middle": [],
                "last": "Miltenyi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Miltenyi Biotec GmbH",
                    "location": {
                        "settlement": "Bergisch-Gladbach",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Ilja",
                "middle": [],
                "last": "Demuth",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Marcel",
                "middle": [
                    "A"
                ],
                "last": "M\u00fcller",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Miltenyi Biotec GmbH",
                    "location": {
                        "settlement": "Bergisch-Gladbach",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Martin",
                "middle": [],
                "last": "Witzenrath",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Norbert",
                "middle": [],
                "last": "Suttorp",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Florian",
                "middle": [],
                "last": "Kern",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "JPT Peptide Technologies GmbH",
                    "location": {
                        "settlement": "Berlin",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Ulf",
                "middle": [],
                "last": "Reimer",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "JPT Peptide Technologies GmbH",
                    "location": {
                        "settlement": "Berlin",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Holger",
                "middle": [],
                "last": "Wenschuh",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Christian",
                "middle": [],
                "last": "Drosten",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin Berlin",
                    "location": {
                        "settlement": "Berlin",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Victor",
                "middle": [
                    "M"
                ],
                "last": "Corman",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin Berlin",
                    "location": {
                        "settlement": "Berlin",
                        "country": "Germany"
                    }
                },
                "email": ""
            },
            {
                "first": "Claudia",
                "middle": [],
                "last": "Giesecke-Thiel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Leif",
                "middle": [
                    "Erik"
                ],
                "last": "\u00a7#",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Sander",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Charit\u00e9 -Universit\u00e4tsmedizin",
                    "location": {
                        "addrLine": "26 Berlin 27"
                    }
                },
                "email": ""
            },
            {
                "first": "Andreas",
                "middle": [],
                "last": "Thiel",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Si-M / \"Der Simulierte Mensch\" a science framework of Technische Universit\u00e4t Berlin",
                    "location": {}
                },
                "email": "andreas.thiel@charite.de"
            }
        ]
    },
    "abstract": [
        {
            "text": "42 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a rapidly 43 unfolding pandemic, overwhelming health care systems worldwide 1 . Clinical manifestations of 44 Coronavirus-disease 2019 (COVID-19) vary broadly, ranging from asymptomatic infection to 45 acute respiratory failure and death 2 , yet the underlying mechanisms for this high variability are 46 still unknown. Similarly, the role of host immune responses in viral clearance of COVID-19 47 remains unresolved. For SARS-CoV (2002/03), however, it has been reported that CD4 + T cell 48 responses correlated with positive outcomes 3,4 , whereas T cell immune responses to SARS-49",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "CoV-2 have not yet been characterized. Here, we describe an assay that allows direct detection 50",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "and characterization of SARS-CoV-2 spike glycoprotein (S)-reactive CD4 + T cells in peripheral 51",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "blood. We demonstrate the presence of S-reactive CD4 + T cells in 83% of COVID-19 patients, 52",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "as well as in 34% of SARS-CoV-2 seronegative healthy donors (HD), albeit at lower 53 frequencies. Strikingly, S-reactive CD4 + T cells in COVID-19 patients equally targeted N-54",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "terminal and C-terminal epitopes of S whereas in HD S-reactive CD4 + T cells reacted almost 55",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "exclusively to the C-terminal epitopes that are a) characterized by higher homology with spike 56 glycoprotein of human endemic \"common cold\" coronaviruses (hCoVs), and b) contains the S2 57 subunit of S with the cytoplasmic peptide (CP), the fusion peptide (FP), and the transmembrane 58 domain (TM) but not the receptor-binding domain (RBD). In contrast to S-reactive CD4 + T 59 cells in HD, S-reactive CD4 + T cells from COVID-19 patients co-expressed CD38 and HLA-60 DR, indivative of their recent in vivo activation. Our study is the first to directly measure SARS-61",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "CoV-2-reactive T cell responses providing critical tools for large scale testing and 62 characterization of potential cross-reactive cellular immunity to SARS-CoV-2. The presence of 63",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "pre-existing SARS-CoV-2-reactive T cells in a subset of SARS-CoV-2 na\u00efve HD is of high 64",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "interest but larger scale prospective cohort studies are needed to assess whether their presence 65 is a correlate of protection or pathology for COVID-19. Results of such studies will be key for 66 a mechanistic understanding of the SARS-CoV-2 pandemic, adaptation of containment 67 methods and to support vaccine development. 68 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "(which was not peer-reviewed) The copyright holder for this preprint .",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": ". Remarkably, S-reactive CD4 + T cells could also be detected in 23 114",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "(34%) of 68 HD, albeit at lower frequencies compared with COVID-19 patients (Figure 2e ). 115",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 76,
                    "end": 86,
                    "text": "(Figure 2e",
                    "ref_id": "FIGREF24"
                }
            ],
            "section": "(Supplementary"
        },
        {
            "text": "These HD are henceforth defined as reactive healthy donors (RHD). Thereof, S-I-reactive CD4 + 116",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "T cells could only be detected in 6 of these 23 RHD, i.e. in 8.8% of all HD. All HD were 117 negative for IgG antibodies specific for S subunit 1 (S1) in contrast to COVID-19 patients 118 (Figure 2f ). We also ruled out early SARS-CoV-2 infection in 10 RHD by PCR standard 119 diagnosis of nasopharyngeal swabs (data not shown). 120 121",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 188,
                    "end": 198,
                    "text": "(Figure 2f",
                    "ref_id": "FIGREF24"
                }
            ],
            "section": "(Supplementary"
        },
        {
            "text": "Spike N-terminal versus C-terminal CD4 + T cell reactivity delineates COVID-19 patients 122 from RHD 123",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "S-reactive CD4 + T cells in COVID-19 equally targeted both N-terminal (S-I) and C-terminal 124",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "peptide pools (S-II) of S (Figure 2d ). In contrast, S-reactive CD4 + T cells from HD exhibited a 125 significantly stronger reactivity to the C-terminal peptide pool S-II, characterized by higher 126",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 26,
                    "end": 36,
                    "text": "(Figure 2d",
                    "ref_id": "FIGREF24"
                }
            ],
            "section": "(Supplementary"
        },
        {
            "text": "homology to spike glycoprotein of HCoV, compared to the N-terminal pool S-I (Figure 2d ). 127",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 76,
                    "end": 86,
                    "text": "(Figure 2d",
                    "ref_id": "FIGREF24"
                }
            ],
            "section": "(Supplementary"
        },
        {
            "text": "The data suggest that S-reactivity among CD4 + T cells in SARS-CoV-2-na\u00efve HD originated 128 from previous immune responses against HCoV. Therefore, we additionally tested 18 of the 68 129",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "HD for the presence of antibodies specific for the four HCoV (229E, NL63, HKU1, OC43). 130 We detected IgG antibodies against the four HCoV in all tested HD, regardless of the presence 131 of measurable S-reactive CD4 + T cells (Supplementary Figure 4) , showing that S-132 (cross-)reactive CD4 + T cells from HD do not correlate with antibody levels against HCoVs. 133 This is in line with findings from other anti-viral CD4 + T cell responses such as in the course 134 of yellow fever vaccination (YFV-17D). Only at very early time points after YFV-17D 135",
            "cite_spans": [
                {
                    "start": 87,
                    "end": 90,
                    "text": "130",
                    "ref_id": null
                },
                {
                    "start": 359,
                    "end": 369,
                    "text": "HCoVs. 133",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 243,
                    "end": 252,
                    "text": "Figure 4)",
                    "ref_id": null
                }
            ],
            "section": "(Supplementary"
        },
        {
            "text": "vaccination CD4 + T cell responses correlated with generation of high titers of neutralizing 136",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "antibodies measured at later time points such as day 14 25 . 137 138",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(Supplementary"
        },
        {
            "text": "Recent studies on SARS-CoV-2 serology have raised the question whether antibody studies are 140 sufficient to identify individuals with mild or asymptomatic courses of COVID-19 7,10 or 141 whether additional, cellular signatures are needed to identify acute or past infections. Here, we 142 assessed additional activation marker profiles on S-reactive T cells from COVID-19 patients. 143",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specific activation signatures of S-reactive CD4 + T cells in COVID-19 patients 139"
        },
        {
            "text": "Expression of CD38, HLA-DR and Ki-67 has previously been shown to reliably characterize 19 patients, considerable proportions of peripheral CD4 + and CD8 + T cells co-expressed CD38 152",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specific activation signatures of S-reactive CD4 + T cells in COVID-19 patients 139"
        },
        {
            "text": "and HLA-DR (data not shown), which, however, could not be re-activated with our S peptide 153 pools in vitro. These findings are in line with results of a recent study showing refractory T cell 154 signatures in COVID-19 patients 31 and also a proportion of these CD38 + HLADR + CD4 + T cells 155 may target other structural proteins of SARS-CoV-2. We also show that the presence of S-156 reactive CD4 + T cells and in particular of CD38 expressing cells among S-reactive CD4 + T cells 157 exhibited a high variability among patients in the course of COVID-19 disease (Figure 3g,h) . 158 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 568,
                    "end": 581,
                    "text": "(Figure 3g,h)",
                    "ref_id": "FIGREF26"
                }
            ],
            "section": "Specific activation signatures of S-reactive CD4 + T cells in COVID-19 patients 139"
        },
        {
            "text": "(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.17.20061440 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specific activation signatures of S-reactive CD4 + T cells in COVID-19 patients 139"
        },
        {
            "text": "Our study demonstrates the presence of S-reactive CD4 + T cells in COVID-19 patients, and in 161 a subset of SARS-CoV-2 seronegative HD. In light of the very recent emergence of SARS-162",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "CoV-2, our data raise the intriguing possibility that pre-existing S-reactive T cells in a subset 163",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "of SARS-CoV-2 seronegative HD represent cross-reactive clones raised against S-proteins, 164",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "probably acquired as a result of previous exposure to HCoV. Endemic HCoV account for about 165 20% of \"common cold\" upper respiratory tract infections in humans. HCoV infections are 166",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "ubiquitous, but they display a winter seasonality in temperate regions 32-34 . Based on 167 epidemiological data indicating an average of two episodes of \"common cold\" per year in the 168 adult population, it may be extrapolated that the average adult contracts a HCoV infection on 169",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "average every two to three years. Protective antibodies may wane in the interim but cellular 170 immunity could remain 15,35 . Although the overall amino acid sequence homology of spike 171 glycoproteins is relatively low among HCoV, there is an overlap of MHC-II epitopes located 172",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "especially in the C-terminal domain of the here used peptide pools ( Figure 1a , Supplementary 173 Figure 1 ). This may explain the preferential reactivity of CD4 + T cells to the C-terminal domain 174",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 69,
                    "end": 78,
                    "text": "Figure 1a",
                    "ref_id": "FIGREF22"
                },
                {
                    "start": 99,
                    "end": 107,
                    "text": "Figure 1",
                    "ref_id": "FIGREF22"
                }
            ],
            "section": "160"
        },
        {
            "text": "in one third of SARS-CoV-2 seronegative HD.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "160"
        },
        {
            "text": "The biological role of pre-existing SARS-CoV-2 S-cross-reactive CD4 + T cells in 34% of HD 176",
            "cite_spans": [],
            "ref_spans": [],
            "section": "175"
        },
        {
            "text": "remains unclear for now. However, these cells may represent the key to understanding the 177 vastly divergent manifestations of SARS-CoV-2 disease courses, and particularly the suspected 178",
            "cite_spans": [],
            "ref_spans": [],
            "section": "175"
        },
        {
            "text": "high rate of asymptomatic infections in children and young adults assuming that these S-cross-179 reactive CD4 + T cells have a protective role in SARS-CoV-2 infection. Since children and 180 young adults have on average more frequent social contacts than the elderly, one might expect 181 a higher transmission rate and HCoV prevalence in the former. This assumption would need to 182 be investigated in future longitudinal studies assessing the presence of pre-existing SARS-CoV-183",
            "cite_spans": [],
            "ref_spans": [],
            "section": "175"
        },
        {
            "text": "2-cross-reactive CD4 + T cells and their impact on the susceptibility to SARS-CoV-2 infcetion 184 and age-realted clinical outcomes of COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "175"
        },
        {
            "text": "SARS-CoV neutralizing antibodies are associated with convalescence, and they have been 186 detected 12 months after disease 11 . However, the durability of neutralizing antibody responses 187",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "against SARS-CoV-2 currently remains unknown. Antibodies against HCoV can wane within 188 months after infection, although HCoV re-infection is accompanied by low-level and short-189 lived virus shedding with only mild symptoms of short duration 12 pointing towards residual 190",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "immunity. Cellular immunity has not yet been studied in this context. The extent to which and 191",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "how SARS-CoV-2 specific humoral or cellular immunity mediates durable protection against 192 reinfection is unknown but will be one of the critically important fields of research in the 193 coming months. It has been demonstrated in mouse models that CD4 + as well as CD8 + T cell 194 responses directed against structural proteins such as spike or nucleocapsid protein of CoV critically contribute to viral clearance 17,36,37 . 196",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "To our knowledge, this study represents the first report of cellular SARS-CoV-2-cross-197 reactivity in human T cells. Our results provide a decisive rationale to initiate worldwide 198",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "prospective studies to assess the contribution of pre-existing SARS-CoV-2-cross-reactive 199 immunity (potential regional differences) to clinical outcomes of SARS-CoV-2-infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "185"
        },
        {
            "text": "Together with currently introduced, novel serology tests, the data generated by such studies 201 may critically inform evidence-based risk evaluation, patient monitoring, adaptation of 202 containment methods, and last but not least, vaccine development. 203 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "200"
        },
        {
            "text": "The copyright holder for this preprint Anti-SARS-CoV-2 IgG ELISA was performed using a commercial kit (EUROIMMUN 224",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "Medizinische Labordiagnostika AG) as described and validated before 38 . Recombinant 225",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "immunofluorescence assays (rIFA) to determine IgG titers against HCoV was done by using 226",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "VeroB4 cells expressing cloned recombinant coronavirus spike proteins from HCoV-229E, 227",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "HCoV-NL63, HCoV-OC43, HCoV-HKU1 as described in Corman et al. 39 .",
            "cite_spans": [
                {
                    "start": 62,
                    "end": 64,
                    "text": "39",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "Cell isolation and stimulation 230",
            "cite_spans": [],
            "ref_spans": [],
            "section": "229"
        },
        {
            "text": "Peripheral blood mononuclear cells (PBMC) were isolated from heparinized whole blood by 231 gradient density centrifugation according to manufacturer's instructions (Leucosep tubes, 232",
            "cite_spans": [],
            "ref_spans": [],
            "section": "229"
        },
        {
            "text": "Greiner; Biocoll, Bio&SELL). Stimulation was conducted with 5x10 6 PBMC in RPMI 1640 233 medium (Gibco) supplemented with 10% heat inactivated AB serum (Pan Biotech), 100 U/ml MACSQuant \u00d2 Analyzer 16. Instrument performance was monitored daily with Rainbow 262",
            "cite_spans": [],
            "ref_spans": [],
            "section": "229"
        },
        {
            "text": "Calibration Particles (BD).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "229"
        },
        {
            "text": "Data analysis and statistics 265",
            "cite_spans": [],
            "ref_spans": [],
            "section": "264"
        },
        {
            "text": "Flow cytometry data were analyzed with FlowJo 9.9.6 (FlowJo LLC). Prism 5 (GraphPad Inc.) 266",
            "cite_spans": [],
            "ref_spans": [],
            "section": "264"
        },
        {
            "text": "was used for plotting and statistical analysis. Non-parametric testing was used to compare cell 267 frequencies and antibody titers between groups (two-tailed Mann-Whitney U test). n indicates 268 the number of donors. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "264"
        },
        {
            "text": ". CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "305"
        },
        {
            "text": "The copyright holder for this preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Comparison of anti-spike glycoprotein subunit 1 (S1) IgG titers (ratio normalized to calibrator well) of HD (n=44), RHD (n=23) and P (n=18). * p<0.05, ** p<0.01, *** p<0.001 as calculated by two-tailed Mann-Whitney U test. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        },
        {
            "text": "(which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.17.20061440 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "(which was not peer-reviewed)"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "COVID-19 in real time",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Gardner",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Infect. Dis",
            "volume": "3099",
            "issn": "",
            "pages": "19--20",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in 274",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "T cell-mediated immune response to respiratory coronaviruses",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "T Cell Responses to Whole SARS Coronavirus in Humans",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J. Immunol",
            "volume": "181",
            "issn": "",
            "pages": "5490--5500",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "M"
                    ],
                    "last": "Corman",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Euro Surveill",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.2807/1560-7917.ES.2020.25.3.2000045"
                ]
            }
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Laboratory diagnosis of emerging human coronavirus infections -the state of the art",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Loeffelholz",
                    "suffix": ""
                },
                {
                    "first": "Y.-W",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Virological assessment of hospitalized patients with COVID-2019",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "W\u00f6lfel",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "1",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1038/s41586-020-2196-x"
                ]
            }
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Nowcasting and forecasting the potential domestic and international spread of the 285 2019-nCoV outbreak originating in Wuhan, China: a modelling study",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Leung",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Leung",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "689--697",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "A serological assay to detect SARS-CoV-2 seroconversion in humans",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Amanat",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.17.20037713"
                ]
            }
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "SARS-CoV-2 specific antibody responses in COVID-19 patients",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "M A"
                    ],
                    "last": "Okba",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.18.20038059"
                ]
            }
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "T Cell Responses to Whole SARS Coronavirus in Humans",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J. Immunol",
            "volume": "181",
            "issn": "",
            "pages": "5490--5500",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "The time course of the immune response to experimental 292 coronavirus infection of man Nasal washings",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Callow",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "F"
                    ],
                    "last": "Parry",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sergeant",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A J"
                    ],
                    "last": "Tyrrell",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "435--446",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Human CD4+ Memory T-lymphocyte 294 Responses to SARS Coronavirus Infection",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Libraty",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "O&apos;neil",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Baker",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "P"
                    ],
                    "last": "Acosta",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Olveda",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Virology",
            "volume": "368",
            "issn": "",
            "pages": "317--321",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein 296 epitopes in unexposed individuals",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Int. Immunol",
            "volume": "21",
            "issn": "",
            "pages": "63--71",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Vaccine",
            "volume": "34",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "144 recently in vivo activated human T cells during acute and chronic infection 26-30 . Notably, S-145 reactive CD4 + T cells from COVID-19 patients largely expressed CD38, HLA-DR and Ki-67 146 (Figure 3a-d). The majority of S-reactive T cells in COVID-19 patients co-expressed CD38 and 147 HLA-DR (Figure 3e) characteristic for effector T cell responses during acute viral 148infections 26,28 whereas CD38 and Ki-67 co-expression was more variable(Figure 3f). By 149 contrast, S-reactive CD4 + T cells from HD did not express CD38, HLA-DR and Ki-67, or only 150 at low frequencies(Figure 3b-f), and co-expression was not observed(Figure 3e, f). In COVID-151",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "234 penicillin (Biochrom), 0.1 mg/ml streptomycin (Biochrom) and PepMix TM SARS-CoV-2 spike 235 glycoprotein (JPT) peptide pool 1 or 2 in the presence of 1 \u00b5g/ml purified anti-CD28 (clone 236 CD28.2, BD Biosciences). The PepMix TM SARS-CoV-2 spike glycoprotein pool 1 covering 237 the N-terminal amino acid (aa) residues 1-643 (abbreviated to \"S-I (N-term)\") contained 158 238 15-mers overlapping by 11 aa. PepMix TM SARS-CoV-2 spike glycoprotein pool 2 covered the 239 C-terminal aa residues 633-1273 (abbreviated to \"S-II (C-term)\") containing 156 15-mers 240 overlapping by 11 aa and one 17-mer at the C-terminus, i.e. 157 peptides in total. Both peptide 241 pools were used at 1 \u00b5g/ml per peptide, respectively. Further details on the peptide pools and 242 predicted MHC-II epitopes are given in Figure 1, Supplementary Figure 1 and Supplementary 243 Table 2. Stimulation controls were performed with equal concentrations of DMSO in PBS 244 (unstimulated) or 1.5 mg SEB/1.0 mg TSST1 (Sigma-Aldrich) and PepMix TM HCMVA (pp65) 245 (>90%) (JPT) in the presence of 1 \u00b5g/ml purified anti-CD28 (clone CD28.2, BD Biosciences) 246 as positive controls, respectively. Incubation was performed at 37\u02daC, 5% CO2 for 16 h with 10 247 \u00b5g/ml brefeldin A (Sigma-Aldrich) added after 2 h. 248 249 Flow Cytometry 250 Stimulation was stopped by incubation in 20 mM EDTA for 5 min and surface staining 251 conducted for 15 min with the following fluorochrome conjugated antibodies titrated to their 252 optimal concentrations: CD38-PE-Vio770 (clone REA671, Miltenyi), CD69-APC-Cy7 (FN50, 253 Biolegend), HLAD-DR-VioGreen (REA805, Miltenyi), CD4-BrilliantViolet605 (RPA-T4, 254 Biolegend), CD8-PerCP (SK1, Biolegend) with 1 mg/ml Beriglobin (CSL Behring) added prior 255 to the staining. For exclusion of dead cells, Zombie Yellow fixable viability staining (Biolegend) 256 was added for the last 10 min of incubation. Fixation and permeabilization were performed with 257 eBioscience TM FoxP3 fixation and PermBuffer (Invitrogen) according to the manufacturer's 258 protocol and intracellular staining carried out for 30 min in the dark at room temperature with 259 Beriglobin added prior to intracellular staining with 4-1BB-PE (clone 4B4-1, BD), CD40L-260 APC (5C8, Miltenyi) and Ki-67-AlexaFluor488 (B56, BD). Samples were measured on a 261",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": ". Mitchison, N. A. T-cell-B-cell cooperation. 4, 1599-1601 (2004).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Yang, Z. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Zhu, Z. et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Natl. Acad. Sci. 104, 12123-12128 (2007).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Ju, B. et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv 2020.03.21.990770 (2020).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Sattler, A. et al. Cytokine-induced human IFN-\u03b3-secreting effector-memory Th cells in chronic autoimmune 312 inflammation. Blood 113, 1948-1956 (2009).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "Schoenbrunn, A. et al. A Converse 4-1BB and CD40 Ligand Expression Pattern Delineates Activated Regulatory T 314 Cells (Treg) and Conventional T Cells Enabling Direct Isolation of Alloantigen-Reactive Natural Foxp3+ Treg. J.315Immunol. 189, 5985-5994 (2012).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "Kohler, S. et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur. J. Immunol. 317 (2012). doi:10.1002/eji.201142306 318 26. Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 319 (2002). doi:10.1038/nm0402-379 320 27. Blom, K. et al. Temporal Dynamics of the Primary Human T Cell Response to Yellow Fever Virus 17D As It Matures 321 from an Effector-to a Memory-Type Response. J. Immunol. (2013). doi:10.4049/jimmunol.1202234 322 28. Callan, M. F. C. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to 323 Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "Miller, J. D. et al. Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Immunity (2008). doi:10.1016/j.immuni.2008.02.020 326 30. Schulz, A. R. et al. Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to 327 Primary Viral Infection in Elderly Humans. J. Immunol. (2015). doi:10.4049/jimmunol.1500598 328 31. Diao, B. et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 ( COVID-19 ).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "329 medRxiv (2020). doi:https://doi.org/10.1101/2020.02.18.20024364 .",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "Tyrrell, D. A. J. Common colds and Related Diseases. (1965).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "Lidwell, O. M. & Williams, R. E. The epidemiology of the common cold. I. J. Hyg. (Lond). 59, 309-319 (1961).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "Gaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P. & Templeton, K. E. Epidemiology and clinical presentations of 333 the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time 334 PCR method. J. Clin. Microbiol. 48, 2940-2947 (2010).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental 336 coronavirus infection of man. Epidemiol. Infect. 105, 435-446 (1990).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K. & Perlman, S. Virus-Specific Memory CD8 T Cells Provide 338 Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection. J. Virol. 88, 11034-339 11044 (2014).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "Wang, B. et al. Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 341 104, 200-206 (2004).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "Okba, N. M. A. et al. Severe Acute Respiratory Syndrome Coronavirus 2\u2212Specific Antibody Responses in Coronavirus 343 Disease 2019 Patients. Emerg. Infect. Dis. J. 26, 2020.03.18.20038059 (2020).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "Corman, V. M. et al. Assays for laboratory confirmation of novel human coronavirus (HCOV-EMC) infections.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "Figure 1",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "Structural domains, homology and MHC-II epitopes of the SARS-CoV-2 spike glycoprotein. a, SARS-CoV-2 spike glycoprotein (1237 amino acids (aa)) is separated at the cleavage site (CS) into subunit S1 harboring the receptor-binding domain (RBD) and subunit S2containing the fusion peptide (FP), the transmembrane domain (TM) and the cytoplasmic peptide (CP). Sequence homology of spike glycoprotein of SARS-CoV-2 to SARS-CoV and HCoV strains NL63, 229E, HKU1 and OC43 was calculated as percentage of aa identity in sliding windows of 10 aa and is depicted as grey scale bars. Known SARS-CoV MHC-II epitopes are indicated as small lines below and sequences are listed in Supplementary Table 2. Homology is depicted for each reported MHC-II epitope in Supplementary Figure 1. SARS-CoV-2 PepMix TM 1 (N-term) (refered to as S-I) spans over the N-terminal and SARS-CoV-2 PepMix TM 2 (C-term) (refered to as S-II) over the C-terminal part of S. b, Proportion of sequence identity of the N-terminal and C-terminal parts of SARS-CoV-2 spike glycoprotein to the spike glycoproteins of HCoV strains NL63,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF24": {
            "text": "SARS-CoV-2 spike glycoprotein-reactive CD4 + T cells in COVID-19 patients and healthy donors. a, Gating strategy to detect SARS-CoV-2-reactive CD4 + T cells after 16 hours in vitro stimulation with PepMix TM SARS-CoV-2 spike glycoprotein peptide pool 1 (S-I (N-term)) and 2 (S-II (C-term)). Representative result of one COVID-19 patient is depicted. b, c, Representative plots displaying CD40L and 4-1BB expression on CD4 + T cells of COVID-19 patients (P), healthy donors (HD) and reactive healthy donors (RHD) after 16 hours in vitro stimulation with S-I (N-term) or S-II (C-term). Numbers indicate percent of total CD4 + T cells. d, Comparison of S-I (N-term)-or S-II (C-term)-reactive CD40L + 4-1BB + frequencies of RHD (n=23) and COVID-19 patients (n=18). e, Ratio of S-I (N-term)-or S-II (C-term)-reactive individuals within the cohort of COVID-19 patients and HD. f,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "Figure 2",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "CD38, HLA-DR and Ki-67 expression of SARS-CoV-2 S-I and S-II-reactive CD4 + T cells discriminates SARS-CoV-2 patients from reactive healthy donors. a, Representative examples of HLA-DR or Ki-67 against CD38 expression on S-II (C-term)-reactive CD4 + T cells (red dots) compared to total CD4 + T cells (grey contours) in RHD and COVID-19 patients. b-d, Comparison of frequencies of CD38 + , HLA-DR + and Ki67 + cells among S-I (N-term)-and S-II (C-term)-reactive CD4 + T cells in RHD (b,c, n=23; d, n=17) and COVID-19 patients (n=18). * p<0.05, ** p<0.01, *** p<0.001 as calculated by two-tailed Mann-Whitney U test. e, f, Co-expression of HLA-DR + or Ki-67 + and CD38 + among S-II (C-term)-reactive CD4 + T cells from RHD (e, n=23; f, n=17) and COVID-19 patients (n=18). g, h, Frequencies of S-I (N-term)-and S-II (C-term)-reactive CD40L + 4-1BB + CD4 + T cells or CD38 + among S-II (C-term)-reactive cells of COVID-19 patients (n=18) plotted over time (days post symptom onset).",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "We thank Ulf Klein (Leeds, UK) und Hans-Peter Herzel (Berlin) for critical discussion. This 207 work was supported by the German Research Foundation (KFO339 to J.B and F.F., SFB-TR84 208 projects A4, B6 to S.H., B8 to M.M., C6 to M.W., C8, C10 to L.E.S., C9 to M.W, N.S., and by 209 the German Federal Ministry of Education and Research (BMBF-RAPID to S.H., C.D., and 210CAPSyS to M.W., N.S.).",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "20. Meng, T. et al. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS. (2020). 21. Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell (2020). doi:10.1016/j.cell.2020.02.058 22. Frentsch, M. et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat. Med. 11, 1118-1124 (2005).",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}